Combretastatin A4-β-Galactosyl Conjugates for Ovarian Cancer Prodrug Monotherapy

Chemotherapy for ovarian Cancer often causes severe side effects. As candidates for combretastatin A4 (CA4) prodrug for ovarian Cancer prodrug monotherapy (PMT), we designed and synthesized two β-galactose-conjugated CA4s (CA4-βGals), CA4-βGal-1 and CA4-βGal-2. CA4 was liberated from CA4-βGals by β-galactosidase, an Enzyme more strongly expressed in ovarian Cancer cells than normal cells. CA4-βGal-2, which has a self-immolative benzyl linker between CA4 and the β-galactose moiety, was more cytotoxic to ovarian Cancer cell lines than CA4-βGal-1 without a linker. Therefore, CA4-βGal-2 can serve as a platform for the design and manufacture of prodrugs for ovarian Cancer PMT.

Antitumor agent; combretastatin A4; ovarian cancer; prodrug monotherapy; tubulin polymerization inhibitor; β-galactosidase.